Table 2 Overall response rate and early tumor shrinkage 6 weeks after treatment
All (n = 103) | GEMOX (n = 54) | GEMOX plus erlotinib (n = 49) | p-value | |
|---|---|---|---|---|
Early tumor shrinkage at 6 weeks | ||||
10 %≤ | 53 (51.4 %) | 22 40.7 %) | 31 (63.2 %) | 0.03 |
Response at 6 weeks (RECIST) | 18 (17.4 %) | 3 (5.6 %) | 15 (30.6 %) | 0.00 |
Complete response | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | |
Partial response | 18 (17.4 %) | 3 (5.6 %) | 15 (30.6 %) | |
Stable disease | 72 (69.9 %) | 44 (81.5 %) | 28 (57.1) | |
Progressive disease | 13 (12.6 %) | 7 (13.0 %) | 6 (12.2 %) | |
Overall response (RECIST) | 30 (29.0 %) | 10 (18.6 %) | 20 (40.8 %) | 0.02 |
Complete response | 1 (0.9 %) | 1 (1.9 %) | 0 (0.0 %) | |
Partial response | 29 (28.1 %) | 9 (16.7 %) | 20 (40.8 %) | |
Stable disease | 50 (48.5 %) | 32 (59.3 %) | 18 (36.7 %) | |
Progressive disease | 23 (22.3 %) | 12 (22.2 %) | 11 (22.4 %) |